DR. ROBERT LOUIS JESSE, MD
Osteopathic Medicine at Broad Rock Blvd, Richmond, VA
License number
Virginia 0101038637
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
1201 Broad Rock Blvd, Richmond, VA 23249
Phone
(804) 675-5419
(804) 675-5420 (Fax)
(804) 675-5420 (Fax)
Personal information
See more information about ROBERT LOUIS JESSE at radaris.comName
Address
Phone
207 Wexleigh Dr, Richmond, VA 23229
1332 Beaver Dam Rd, Chesapeake, VA 23322
722 Riverside Dr, North Tazewell, VA 24630
2103 Pridgen Rd, Hampton, VA 23663
207 Wexleigh Dr, Richmond, VA 23229
Professional information
Robert Louis Jesse, Richmond VA
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
VCU Health System
1250 E Marshall St, Richmond, VA 23298 Hunter Holmes McGuire Veterans Affairs Medical Center
1201 Broad Rock Blvd, Richmond, VA 23286 VCU Health System
Medical College Of Virginia, Richmond, VA 23219
1250 E Marshall St, Richmond, VA 23298 Hunter Holmes McGuire Veterans Affairs Medical Center
1201 Broad Rock Blvd, Richmond, VA 23286 VCU Health System
Medical College Of Virginia, Richmond, VA 23219
Education:
Virginia Commonwealth University (1984)
Dr. Robert L Jesse, Richmond VA - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
1201 Broad Rock Blvd, Richmond 23249
(804) 675-5419 (Phone), (804) 675-5420 (Fax)
Virginia Commonwealth University INT
1250 E Marshall St, Richmond 23298
(800) 762-6161 (Phone)
(804) 675-5419 (Phone), (804) 675-5420 (Fax)
Virginia Commonwealth University INT
1250 E Marshall St, Richmond 23298
(800) 762-6161 (Phone)
Certifications:
Cardiovascular Disease, 2005, Internal Medicine, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Virginia Commonwealth University School Of Medicine
Graduated: 1984
Med College Va
Graduated: 1985
Graduated: 1987
Graduated: 1990
Virginia Commonwealth University School Of Medicine
Graduated: 1984
Med College Va
Graduated: 1985
Graduated: 1987
Graduated: 1990
Method Of Using Dehydroepiandrosterone And Dehydroepiandrosterone-Sulfate As Inhibitors Of Thrombuxane Production And Platelet Aggregation
US Patent:
5162198, Nov 10, 1992
Filed:
Sep 25, 1991
Appl. No.:
7/765368
Inventors:
David M. Eich - Richmond VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Assignee:
Virginia Commonwealth University - Richmond VA
International Classification:
A01N 102, A61K 3156
US Classification:
435 2
Abstract:
Treating human beings with pharmacological quantities of DHEA results in their blood having increased serum DHEA and DHEA-S and lower rates of platelet aggregation. Reducing the rate of platelet aggregation can significantly reduce the incidence of morbidity and mortality from vascular events such as myocardial infarction and stroke, as well as reduce the occurrence of restenosis following vascular interventions. The concentration of DHEA and DHEA-S in the blood and the pre-incubation time of DHEA and DHEA-S with the blood will affect its impact on platelet aggregation. Hence, prior treatment of patients who are at risk with DHEA may produce the most beneficial affects. In addition, treatment of blood with DHEA-S reduces thromboxane production. Thromboxane is produced after platelets are subjected to many different types of agonists and is responsible for recruiting other platelets to aggregate and form a thrombus; therefore, blocking the production of thromboxane will reduce or prevent platelet aggregation.
Method Of Using Dehydroepiandrosterone And Dehydroepiandrosterone-Sulfate As Inhibitors Of Platelet Aggregation
US Patent:
5110810, May 5, 1992
Filed:
Feb 8, 1991
Appl. No.:
7/652518
Inventors:
David M. Eich - Suffolk VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Assignee:
Virginia Commonwealth University - Richmond VA
International Classification:
A61K 3156
US Classification:
514178
Abstract:
Treating human beings with pharmacological quantities of DHEA results in their blood having increased serum DHEA and DHEA-S and lower rates of platelet aggregation. Reducing the rate of platelet aggregation can significantly reduce the incidence or morbidity and mortality from vascular events such as myocardial infarction and stroke, as well as reduce the occurrence of restenosis following vascular interventions. The concentration of DHEA and DHEA-S in the blood and the pre-incubation time of DHEA and DHEA-S with the blood will affect its impact on platelet aggregation. Hence, prior treatment of patients who are at risk with DHEA may produce the most beneficial affects. In addition, treatment of blood with DHEA-S reduces thromboxane production. Thromboxane is produced after platelets are subjected to many different types of agonists and is responsible for recruiting other platelets to aggregate and form a thrombus; therefore, blocking the production of thromboxane will reduce or prevent platelet aggregation.